Literatura científica selecionada sobre o tema "(Alliance, Ohio)"
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Consulte a lista de atuais artigos, livros, teses, anais de congressos e outras fontes científicas relevantes para o tema "(Alliance, Ohio)".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Artigos de revistas sobre o assunto "(Alliance, Ohio)"
1
Aufderheide, Patricia. "Alliance for Community Media Keynote July 10, 1999, Cincinnati, Ohio". Wide Angle 21, n.º 2 (1999): 126–35. http://dx.doi.org/10.1353/wan.1999.0013.
Texto completo da fonte
2
White, Jeffry L., James W. Altschuld e Yi-Fang Lee. "Evaluating minority retention programs: Problems encountered and lessons learned from the Ohio science and engineering alliance". Evaluation and Program Planning 31, n.º 3 (agosto de 2008): 277–83. http://dx.doi.org/10.1016/j.evalprogplan.2008.03.006.
Texto completo da fonte
3
Deason, Lucinda M., Surendra B. Adhikari, Tracy M. Clopton, Barry Oches e Conrado Jensen. "The Ohio Cross-Cultural Tobacco Control Alliance: Understanding and Eliminating Tobacco-Related Disparities Through the Integration of Science, Practice, and Policy". American Journal of Public Health 100, S1 (abril de 2010): S240—S245. http://dx.doi.org/10.2105/ajph.2009.180505.
Texto completo da fonte
4
Bogert, James R., Jack M. Kibler e Jack K. Schmotzer. "Standardless EDXRF Analysis of Cations in Ion-Exchange Resin-Impregnated Membranes". Advances in X-ray Analysis 30 (1986): 153–63. http://dx.doi.org/10.1154/s037603080002125x.
Texto completo da fonteResumo:
In steam-generating systems of all types, producing and testing pure water is of utmost importance for the life of the system. A 1000-MWe (megawatt electric) power plant generates 6 million pounds of steam per hour if fossil fueled and 11 million pounds per hour if nuclear. Should an impurity have a concentration of only 10 ppb, in a year's time, 550 to 1000 pounds of solids can accumulate in the power-generating cycle. These solids may initiate numerous problems, including preboiler-cycle corrosion, boiler-tube failure, and turbine damage.At the Babcock & Wilcox (B&W) Alliance (Ohio) Research Center and throughout the industry, three principal methods are used to monitor water chemistry. On-line continuous analyzers measure parameters such as pH, conductivity, chloride, and sodium. Grab sampling (followed by laboratory analysis) is used for parameters that are measured less frequently; for example, sulfate. For some parameters, such as corrosion products, special sampling techniques are required. This is because no on-line instruments are available, and grab-samples are not chemically stable. Corrosion products are collected near the sample tap using a 0.45-micron filter-disc followed by a stack of resin-impregnated membranes.
5
Liaqat, Muneezeh, Andrew Turner, Peter Anderson, Bryson Palmer, Sherif Al Taher, Zachariah Koshy, Winifredo de Jesus et al. "Establishing an Anatomic Pathology Laboratory at Cleveland Clinic Abu Dhabi". Archives of Pathology & Laboratory Medicine 142, n.º 9 (1 de setembro de 2018): 1036–46. http://dx.doi.org/10.5858/arpa.2018-0101-ra.
Texto completo da fonteResumo:
Context.— The Department of Anatomic Pathology is a division of the Pathology & Laboratory Medicine Institute at Cleveland Clinic Abu Dhabi. The hospital offers the same model of care as its US-based counterpart the Cleveland Clinic, established in 1921 in Cleveland, Ohio. Pathology services at Cleveland Clinic are internationally acclaimed: the endeavor for Cleveland Clinic Abu Dhabi was to create a parallel facility, with the same standards in a greenfield start-up environment. Objective.— To narrate how we addressed challenges customary in any laboratory start-up and issues distinctive to our setting with the aim to provide a model for others involved in a similar undertaking. Data Sources.— All information in this article is based on published literature obtained by search on internet-based search engines, Clinical and Laboratory Standards Institute, and the authors' firsthand experience. Conclusions.— Key considerations in establishing an anatomic pathology laboratory are careful planning and design, adherence to local and international regulatory standards, selection of equipment and supplies, appropriate staffing, development of a laboratory information system, and sound test validation. In addition to meeting our clinical needs, alliance with the US Cleveland Clinic had an integral role in establishing our laboratory and regional reputation.
6
Uy, Geoffrey L., Jun Yin, Heidi D. Klepin, Shira Dinner, Anthony J. Jaslowski, Stephen A. Strickland, Jane L. Liesveld, John C. Byrd e Richard M. Stone. "Alliance A041701 - a Randomized Phase 2/3 Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia (AML) Receiving Intensive Induction Chemotherapy". Blood 134, Supplement_1 (13 de novembro de 2019): 1366. http://dx.doi.org/10.1182/blood-2019-127142.
Texto completo da fonteResumo:
Uproleselan (GMI-1271) is a novel antagonist of E-selectin, an adhesion molecule expressed on endothelial cells. E-selectin is expressed transiently in the normal vasculature during an inflammatory response and constitutively in the bone marrow (BM). Binding of E-selectin (E-sel) to sialyl Lex, the E-sel ligand (E-sel-L), on the leukemic cell surface activates cell survival pathways and promotes chemotherapy resistance in AML. In preclinical models, blockade of E-selectin with uproleselan disrupts the activation of cell survival pathways and enhanced the efficacy of chemotherapy across multiple AML tumor models. Furthermore, uproleselan protected against chemotherapy-induced mucositis by regulating macrophage trafficking to the site of injury in the gut lining. A previous phase I/II study of uproleselan added to chemotherapy in patients with untreated AML (older adults ≥60 yrs) and relapsed/refractory AML (≥ 18yrs) showed promising remission rates (CR/CRi) and survival outcomes, and reduced rates of mucositis. In the newly diagnosed older patients, high remission rates were achieved overall (CR/CRi 72%) and for the high risk subgroup with sAML (CR/CRi 69%). In this phase 2/3 study, we will test the addition of uproleselan to a standard daunorubicin/cytarabine regimen in older adults with previously untreated AML. The study will enroll patients age ≥ 60 yrs with untreated acute myeloid leukemia. Patients with acute promyelocytic leukemia, activating mutations in FLT3, or evidence of central nervous system involvement are excluded. Subjects are randomized to 7+3 induction (cytarabine + daunorubicin) +/- uproleselan. Subjects achieving a CR/CRi may receive up to 3 cycles of consolidation with intermediate dose cytarabine 2 gm/m2 IV d1-5 +/- uproleselan. The primary phase II objective is to compare the event-free survival (EFS). A sample size of 262 patients was selected for the phase II to detect an improvement in median EFS from 7 months to 11 months (HR= 0.64) with > 95% power, using a log rank test. The phase III primary objective will compare overall survival (OS). For the phase III, a sample size of 335 evaluable patients per arm (670 total inclusive of patients enrolled in phase II) will provide >90% power to detect an improvement in median OS from 12 months to 16 months (HR= 0.75), using a log-rank test. Correlative studies will measure E-selectin ligand on AML blasts and soluble E-selectin and will also measure minimal residual disease after remission induction by multiparameter flow cytometry. A comprehensive geriatric assessment will identify baseline measures associated with EFS and develop a risk model to predict OS among older adults receiving intensive AML therapy. The study is endorsed by SWOG and ECOG-ACRIN and opened to enrollment on 1/16/2019. Figure Disclosures Uy: Astellas: Consultancy; Pfizer: Consultancy; Curis: Consultancy; GlycoMimetics: Consultancy. Dinner:Agios: Consultancy; Pfizer: Consultancy; AstraZeneca: Consultancy. Strickland:Jazz: Consultancy; Sunesis Pharmaceuticals: Research Funding; Pfizer: Consultancy; Kite: Consultancy; Astellas Pharma: Consultancy; AbbVie: Consultancy. Liesveld:Onconova: Other: Data safety monitoring board; Abbvie: Membership on an entity's Board of Directors or advisory committees. Byrd:Acerta: Research Funding; Acerta: Research Funding; Genentech: Research Funding; Janssen: Consultancy, Other: Travel Expenses, Research Funding, Speakers Bureau; Ohio State University: Patents & Royalties: OSU-2S; BeiGene: Research Funding; Janssen: Consultancy, Other: Travel Expenses, Research Funding, Speakers Bureau; BeiGene: Research Funding; Gilead: Other: Travel Expenses, Research Funding, Speakers Bureau; Gilead: Other: Travel Expenses, Research Funding, Speakers Bureau; BeiGene: Research Funding; Novartis: Other: Travel Expenses, Speakers Bureau; Novartis: Other: Travel Expenses, Speakers Bureau; Gilead: Other: Travel Expenses, Research Funding, Speakers Bureau; Pharmacyclics LLC, an AbbVie Company: Other: Travel Expenses, Research Funding, Speakers Bureau; Pharmacyclics LLC, an AbbVie Company: Other: Travel Expenses, Research Funding, Speakers Bureau; Novartis: Other: Travel Expenses, Speakers Bureau; TG Therapeutics: Other: Travel Expenses, Research Funding, Speakers Bureau; Genentech: Research Funding; Genentech: Research Funding; Pharmacyclics LLC, an AbbVie Company: Other: Travel Expenses, Research Funding, Speakers Bureau; Acerta: Research Funding; TG Therapeutics: Other: Travel Expenses, Research Funding, Speakers Bureau; Ohio State University: Patents & Royalties: OSU-2S; Ohio State University: Patents & Royalties: OSU-2S; TG Therapeutics: Other: Travel Expenses, Research Funding, Speakers Bureau; Janssen: Consultancy, Other: Travel Expenses, Research Funding, Speakers Bureau. Stone:Argenx, Celgene, Takeda Oncology: Other: Data and Safety Monitoring Board/Committee: ; AbbVie, Actinium, Agios, Argenx, Arog, Astellas, AstraZeneca, Biolinerx, Celgene, Cornerstone Biopharma, Fujifilm, Jazz Pharmaceuticals, Amgen, Ono, Orsenix, Otsuka, Merck, Novartis, Pfizer, Sumitomo, Trovagene: Consultancy; Novartis, Agios, Arog: Research Funding. OffLabel Disclosure: Uproleselan in AML
7
Hingson, Jesse. "Colombia and the United States: The Making of an Inter‐American Alliance, 1939–1960. By Bradley Lynn Coleman. (Kent, Ohio: Kent State University Press, 2008. Pp.ix, 303. $45.95.)". Historian 72, n.º 3 (1 de setembro de 2010): 641–42. http://dx.doi.org/10.1111/j.1540-6563.2010.00273_12.x.
Texto completo da fonte
8
Bill, Marius, Krzysztof Mrózek, Jessica Kohlschmidt, Deedra Nicolet, Brian Giacopelli, Christopher J. Walker, Dimitrios Papaioannou et al. "Personalized Oncology in Acute Myeloid Leukemia (AML): Validation of the Prognostic Value of the Knowledge Bank Algorithm in Patients (Pts) Treated on Cancer and Leukemia Group B (CALGB)/Alliance Protocols". Blood 134, Supplement_1 (13 de novembro de 2019): 182. http://dx.doi.org/10.1182/blood-2019-128623.
Texto completo da fonteResumo:
Introduction: AML is a heterogeneous disease with diverse patient outcomes. During the last 4 decades, several cytogenetic and molecular markers have been used for risk stratification of AML pts and to guide therapeutic decisions. In 2017, Gerstung et al. (Nat Genet 2017;49:332) used a knowledge bank (KB; i.e., combination of clinical, outcome, cytogenetic and sequencing data of 111 genes from 1,540 AML pts) to generate an algorithm that is able to predict likelihoods for remission, relapse, and mortality in AML pts. The prognostic value of the established KB algorithm was validated in two independent but smaller pt cohorts (Gerstung et al.: n=186 pts; Huet et al. Blood 2018;132:865: n=155 pts). Aims: The aim of our study was to validate the prognostic relevance of the KB algorithm both in our entire large independent adult pt cohort and in age subgroups (i.e., younger [<60 y] and older [≥60 y] pts). We also compared the performance of the KB algorithm with that of another well-established prognostic classification, the 2017 European LeukemiaNet (ELN) genetic risk classification (Döhner et al. Blood 2017;129:424). Methods: We analyzed 1,617 pts (median age: 53 y; 1,048 aged <60 y and 569 aged ≥60 y; including 167 early death [ED] pts who died within 30 days after diagnosis) with de novo AML appropriate for intensive chemotherapy. The mutational status of 80 cancer- and leukemia-associated genes (Eisfeld et al. Leukemia 2017;31:2211) was determined using a targeted next-generation sequencing panel (variants with variant allele fraction < 5% were defined as not mutated) The status of biallelic CEBPA mutations was determined using Sanger sequencing, and an internal tandem duplication of the FLT3 gene using fragment analysis in pretreatment bone marrow or blood samples. All pts were treated on CALGB/Alliance protocols and none received an allogeneic transplant in first complete remission (CR1). Of the genes whose mutational status is included in the KB algorithm, 26% were not included in our sequencing panel, but all 30 genes that had the biggest impact on the algorithm's ability to predict outcome were contained in our panel. Results: We used the 3-y overall survival (OS) rates to compare the KB algorithm prediction with the actual outcome. In the whole cohort, we found the area under the receiver operating characteristic curve (AUC) to be AUCKB = 0.79 (Figure 1A). Of note, AUC = 1.00 means perfect prediction ability whereas AUC = 0.50 denotes lack of prediction ability equal to that of random chance. Concerning other clinical endpoints, we found that the KB approach had the highest AUC for predicting non-remission death (i.e., pts who died without achieving a CR1, AUCKB = 0.84), followed by relapse death (i.e., pts who died after relapse, AUCKB = 0.69), and non-relapse death (i.e., pts who died in CR1, AUCKB = 0.61). Analysis of the 3-y OS in the subgroup of younger pts yielded similar results with an AUCKB = 0.78. Older pts are known to have poorer prognosis and risk stratification is more difficult for this cohort, but, we still found an AUCKB = 0.79 for the KB approach. Next, we compared the predictive value of the KB approach with the current ELN classification and found that KB outperformed the ELN classification in the whole cohort (AUCKB = 0.79 vs AUCELN = 0.53, P<0.001; Figure 1A) as well as in the younger (AUCKB = 0.78 vs AUCELN = 0.51, P<0.001; Figure 1B) and older pt subgroups (AUCKB = 0.79 vs AUCELN = 0.53, P<0.001; Figure 1C). We also compared KB and ELN after excluding ED pts because the ELN risk group is a poor predictor for ED. We found that KB still outperformed the ELN classification in the whole cohort (AUCKB = 0.78 vs AUCELN = 0.71, P<0.001) and in the younger pts (AUCKB = 0.74 vs AUCELN = 0.69, P=0.005). However, in older pts the difference was of borderline significance (AUCKB = 0.75 vs AUCELN = 0.70, P=0.05). Conclusions: Our analysis of a large cohort of 1,617 pts with de novo AML treated with intensive chemotherapy validated the prognostic value of the recently published KB algorithm for the 3-y OS endpoint. Although we found that the KB approach had a high predictive relevance for non-remission death, the AUCs for relapse death and non-relapse death were lower. We also showed that the KB approach had a better predictive value than the current ELN classification but the differences in the AUCs were smaller when ED pts were excluded. Support: CA233338, U24CA196171, U10CA180821, U10CA180882. https://acknowledgments.alliancefound.org Disclosures Kolitz: Boeringer-Ingelheim: Research Funding; Astellas: Research Funding; Roche: Research Funding. Powell:Jazz Pharmaceuticals: Consultancy, Research Funding, Speakers Bureau; Pfizer: Consultancy, Research Funding; Rafael Pharmaceuticals: Consultancy, Research Funding; Novartis: Consultancy, Speakers Bureau; Janssen: Research Funding. Stone:AbbVie, Actinium, Agios, Argenx, Arog, Astellas, AstraZeneca, Biolinerx, Celgene, Cornerstone Biopharma, Fujifilm, Jazz Pharmaceuticals, Amgen, Ono, Orsenix, Otsuka, Merck, Novartis, Pfizer, Sumitomo, Trovagene: Consultancy; Argenx, Celgene, Takeda Oncology: Other: Data and Safety Monitoring Board/Committee: ; Novartis, Agios, Arog: Research Funding. Byrd:Janssen: Consultancy, Other: Travel Expenses, Research Funding, Speakers Bureau; Gilead: Other: Travel Expenses, Research Funding, Speakers Bureau; Ohio State University: Patents & Royalties: OSU-2S; Pharmacyclics LLC, an AbbVie Company: Other: Travel Expenses, Research Funding, Speakers Bureau; Ohio State University: Patents & Royalties: OSU-2S; Ohio State University: Patents & Royalties: OSU-2S; Acerta: Research Funding; TG Therapeutics: Other: Travel Expenses, Research Funding, Speakers Bureau; Acerta: Research Funding; Pharmacyclics LLC, an AbbVie Company: Other: Travel Expenses, Research Funding, Speakers Bureau; Pharmacyclics LLC, an AbbVie Company: Other: Travel Expenses, Research Funding, Speakers Bureau; TG Therapeutics: Other: Travel Expenses, Research Funding, Speakers Bureau; Novartis: Other: Travel Expenses, Speakers Bureau; TG Therapeutics: Other: Travel Expenses, Research Funding, Speakers Bureau; Genentech: Research Funding; Genentech: Research Funding; Genentech: Research Funding; BeiGene: Research Funding; Novartis: Other: Travel Expenses, Speakers Bureau; Gilead: Other: Travel Expenses, Research Funding, Speakers Bureau; Gilead: Other: Travel Expenses, Research Funding, Speakers Bureau; BeiGene: Research Funding; Janssen: Consultancy, Other: Travel Expenses, Research Funding, Speakers Bureau; Acerta: Research Funding; BeiGene: Research Funding; Janssen: Consultancy, Other: Travel Expenses, Research Funding, Speakers Bureau; Novartis: Other: Travel Expenses, Speakers Bureau.
9
Woyach, Jennifer, Amy S. Ruppert, Gabriela Perez, Allison M. Booth, Diane Feldman, Elie G. Dib, Aminah Jatoi et al. "Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)". Blood 134, Supplement_1 (13 de novembro de 2019): 1751. http://dx.doi.org/10.1182/blood-2019-127102.
Texto completo da fonteResumo:
Background The phase 3 trial A041202 solidified the Bruton's Tyrosine Kinase (BTK) inhibitor ibrutinib as a standard of care for older patients with previously untreated CLL by showing superior progression-free survival (PFS) as compared with bendamustine plus rituximab. While ibrutinib is highly effective in previously untreated CLL, there do remain disadvantages to this therapy, specifically the low rate of complete response (CR) and therefore the need for continuous administration, which increases cost and toxicity. In older patients especially, toxicities with ibrutinib are common; 17% of patients had atrial fibrillation and 29% had grade 3 or higher hypertension on the A041202 study. Thus, strategies to decrease the exposure time to ibrutinib are of interest. Venetoclax is an inhibitor of BCL2 that has shown efficacy as a single agent and in combination with monoclonal antibodies, specifically the anti-CD20 monoclonal antibody obinutuzumab for patients with previously untreated CLL. One significant advantage to venetoclax is the ability to produce CRs and minimal residual disease negative (MRD-) responses. In this study, we compare ibrutinib plus obinutuzumab (IO) to ibrutinib plus venetoclax plus obinutuzumab (IVO) with a response-dependent discontinuation. While other studies have been designed with the goal of discontinuation of ibrutinib through combinations with venetoclax, no other study has been presented using a response-dependent discontinuation strategy. Study Design and Methods A041702 is a randomized phase 3 study led by the Alliance for Clinical Trials in Oncology that is currently enrolling through the NCI National Clinical Trials Network (NCTN). CLL patients age 70 years or older who are previously untreated and in need of therapy are eligible. Previous treatment of autoimmune complications with steroids or rituximab is allowed. Patients must have intermediate- or high-risk Rai stage, ECOG performance status 0-2, ANC ≥ 1000/mm3 unless due to marrow involvement, and platelets ≥ 30,000/mm3. CrCl must be ≥ 40 mL/min and AST/ALT ≤ 2.5x upper limit of normal. Patients with hepatitis B must have undetectable viral load, and patients must not have an intercurrent illness that is expected to limit survival to < 5 years. Warfarin and strong inhibitors or inducers of CYP3A4/5 are not permitted. Patients are initially preregistered to the study and submit a peripheral blood sample for central FISH analysis of del(17p). Patients who are registered are randomized 1:1 to Arm 1 (IO) or Arm 2 (IVO), and are stratified by Rai stage and presence of del(17p). IO consists of I daily starting cycle 1 day 1, and O dosed as standard starting cycle 1 day 1 and continuing to cycle 6 day 1. IVO consists of IO as in Arm 1, with V starting cycle 3 day 1 with standard 5-week ramp-up and continuing until cycle 14 day 28. At the end of 14 cycles, patients in both arms undergo response evaluation with central peripheral blood and bone marrow MRD testing. Patients on IO then continue I indefinitely. Patients on IVO who are in a bone marrow MRD- CR discontinue all therapy, and those who are not continue I indefinitely. The primary objective of the study is to compare PFS between IO and IVO using the strategy of response-dependent discontinuation. There is 90% power to detect a hazard ratio for PFS of 0.55 (corresponding to 5-year PFS rates of 70% and 82.187% for IO and IVO, respectively), at a one-sided significance level of 0.025 by a log-rank test. This design requires 128 events and 431 total evaluable patients assuming uniform accrual over the course of 3 years and minimum follow-up of 5 years. The study includes two interim analyses for superiority when 50% and 75% of the expected number of events have been observed and three interim analyses for futility when 25%, 50%, and 75% of the expected number of events have been observed. Conclusions A041702 is an ongoing phase 3 clinical trial using a novel response-dependent discontinuation method. Results of this study have the potential to change the standard of care for older patients with previously untreated CLL. The study is expected to accrue for 3 years beginning January 2019, and we welcome participation from sites throughout the NCTN. Support: U10CA180821, U10CA180882, UG1CA189823, U24CA196171; U10CA180820 (ECOG-ACRIN); https://acknowledgments.alliancefound.org; ClinicalTrials.gov Identifier: NCT03737981 Disclosures Woyach: Janssen: Consultancy, Research Funding; Pharmacyclics LLC, an AbbVie Company: Consultancy, Research Funding; AbbVie: Research Funding; Karyopharm: Research Funding; Loxo: Research Funding; Morphosys: Research Funding; Verastem: Research Funding. Lozanski:Beckman Coulter: Research Funding; Boehringer Ingelheim: Research Funding; Stemline Therapeutics Inc.: Research Funding; Genentec: Research Funding. Ding:Merck: Research Funding; DTRM Biopharma: Research Funding. Hill:Pharmacyclics: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; AstraZeneca: Consultancy, Honoraria; Celegene: Consultancy, Honoraria, Research Funding; Seattle Genetics: Consultancy, Honoraria; Takeda: Research Funding; Amgen: Research Funding; TG therapeutics: Research Funding; Abbvie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Genentech: Consultancy, Research Funding; Kite: Consultancy, Honoraria; Gilead: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Stone:Argenx, Celgene, Takeda Oncology: Other: Data and Safety Monitoring Board/Committee: ; Novartis, Agios, Arog: Research Funding; AbbVie, Actinium, Agios, Argenx, Arog, Astellas, AstraZeneca, Biolinerx, Celgene, Cornerstone Biopharma, Fujifilm, Jazz Pharmaceuticals, Amgen, Ono, Orsenix, Otsuka, Merck, Novartis, Pfizer, Sumitomo, Trovagene: Consultancy. Byrd:Janssen: Consultancy, Other: Travel Expenses, Research Funding, Speakers Bureau; BeiGene: Research Funding; Pharmacyclics LLC, an AbbVie Company: Other: Travel Expenses, Research Funding, Speakers Bureau; Gilead: Other: Travel Expenses, Research Funding, Speakers Bureau; Pharmacyclics LLC, an AbbVie Company: Other: Travel Expenses, Research Funding, Speakers Bureau; Genentech: Research Funding; Ohio State University: Patents & Royalties: OSU-2S; Janssen: Consultancy, Other: Travel Expenses, Research Funding, Speakers Bureau; Gilead: Other: Travel Expenses, Research Funding, Speakers Bureau; Novartis: Other: Travel Expenses, Speakers Bureau; Gilead: Other: Travel Expenses, Research Funding, Speakers Bureau; Pharmacyclics LLC, an AbbVie Company: Other: Travel Expenses, Research Funding, Speakers Bureau; TG Therapeutics: Other: Travel Expenses, Research Funding, Speakers Bureau; Novartis: Other: Travel Expenses, Speakers Bureau; Ohio State University: Patents & Royalties: OSU-2S; Acerta: Research Funding; Novartis: Other: Travel Expenses, Speakers Bureau; BeiGene: Research Funding; Ohio State University: Patents & Royalties: OSU-2S; TG Therapeutics: Other: Travel Expenses, Research Funding, Speakers Bureau; Acerta: Research Funding; Genentech: Research Funding; BeiGene: Research Funding; Genentech: Research Funding; Acerta: Research Funding; TG Therapeutics: Other: Travel Expenses, Research Funding, Speakers Bureau; Janssen: Consultancy, Other: Travel Expenses, Research Funding, Speakers Bureau.
10
Papaioannou, Dimitrios, Deedra Nicolet, Kellie J. Archer, Allison Walker, Krzysztof Mrózek, Andrew J. Carroll, Jessica Kohlschmidt et al. "Next-Generation RNA Sequencing-Based Analysis Identifies a Novel Set of Prognostic Micrornas (miRs) in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)". Blood 134, Supplement_1 (13 de novembro de 2019): 2694. http://dx.doi.org/10.1182/blood-2019-125727.
Texto completo da fonteResumo:
Background: Aberrant expression levels of several miRs have been reported to independently associate with outcome of patients (pts) with CN-AML. In these reports, miR expression was profiled using microarray assays, which interrogate a selected subset of miRs. The advent of next-generation sequencing (NGS) has allowed unbiased measurement of miR expression, but, to our knowledge, NGS has not been used to identify miRs associated with prognosis of AML pts. Here, we analyze small RNA sequencing (smRNA-seq) data from a large cohort of younger adults with CN-AML, for whom outcome data were available, with the goal to identify new prognostic miRs. Methods: We performed smRNA-seq in 281 younger adults (aged 18-59 y) with de novo CN-AML. Cytogenetic analyses were performed in Cancer and Leukemia Group B (CALGB)/Alliance institutional laboratories using standard banding techniques; mutational analyses were done centrally using a targeted DNA sequencing platform. All pts were treated on frontline CALGB/Alliance protocols. Results: We first evaluated which miRs associated with overall survival (OS) in univariable analysis; we detected 9 such miRs. We then used a machine-learning approach, namely random forests, to identify miRs whose concomitant expression could generate an effective outcome predictor in CN-AML. To account for the effect of co-existing prognostic gene mutations, we included the European LeukemiaNet (ELN) risk group status in the random forest analyses. A total of 8 prognostic miRs were identified, 4 of which were also found to be prognostic in univariable analysis (underlined below), thus bringing the total number of unique prognostic miRs to 13: miR-511, miR-1193, miR-155, miR-4517, miR-3681, miR-2355, miR-628, miR-1266, miR-6715a, miR-1180, miR-6715b, miR-132, miR-146b. We used partitioning around medoids to divide our pts into clusters, based on the combined expression levels of the 13 prognostic miRs. Two such clusters were identified: cluster 1 comprised 173 pts and cluster 2 contained 108 pts. Regarding pretreatment and molecular features, pts in cluster 1 had lower percent of bone marrow blasts (P=.04), and had more frequently biallelic CEBPA mutations (P<.001) and less frequently internal tandem duplications of the FLT3 gene (P<.001), RUNX1 (P=.02) and WT1(P=.03) mutations than pts in cluster 2. In outcome analyses, pts in cluster 1 had a higher complete remission rate (CR; 91% vs 73%,P<.001) and a longer disease-free survival (DFS; 5-y rates 52% vs 16%, P<.001) and OS (5-y rates 60% vs 19%,P<.001). In multivariable analysis, cluster 1 status remained significantly associated with higher odds of achieving a CR (P=.001) and longer DFS (P<.001) and OS (P<.001), after adjusting for other covariates. Regarding accuracy of outcome prediction, our composite model had a concordance index of 0.687. When ranked according to importance for prognosis, miR-511 expression was the most significant determinant among the random forest model parameters. To evaluate the reproducibility of our findings, we performed analyses in the publicly available TCGA dataset (Ley et al. NEJM 2013;368:2059). Eighty-eight CN-AML pts with miR expression and survival data were available in the TCGA cohort. As TCGA pts are not classified according to ELN risk groups, we could not directly reproduce the random forest-based cluster analysis. However, a univariable analysis showed that miR-511 and miR-628 expression levels were also prognostic in the TCGA dataset. Next, we evaluated whether the identified prognostic miRs have functional relevance in AML. We focused on miR-511, which was the most important determinant of our outcome predictor and has not been previously studied in AML. Among 6 AML cell lines tested, MV4-11 had the most abundant expression of miR-511. Functional silencing of miR-511 in MV4-11 cells decreased both their viability (as measured by Annexin-PI staining and flow-cytometry, P=.004) and proliferative capacity (as measured by WST1 reagent degradation, P<.001). Conclusion: Unbiased profiling of miRs using smRNA-seq has identified a novel set of 13 miRs with prognostic significance in CN-AML. MiR expression-based cluster status independently associates with clinical outcome of CN-AML pts. Our preliminary in vitro experiments have shown that miR-511, whose association with prognosis was the strongest among the newly identified prognostic miRs, is functionally relevant in AML. Disclosures Uy: Astellas: Consultancy; Pfizer: Consultancy; Curis: Consultancy; GlycoMimetics: Consultancy. Powell:Rafael Pharmaceuticals: Consultancy, Research Funding; Novartis: Consultancy, Speakers Bureau; Jazz Pharmaceuticals: Consultancy, Research Funding, Speakers Bureau; Pfizer: Consultancy, Research Funding; Janssen: Research Funding. Kolitz:Astellas: Research Funding; Boeringer-Ingelheim: Research Funding; Roche: Research Funding. Byrd:Acerta: Research Funding; TG Therapeutics: Other: Travel Expenses, Research Funding, Speakers Bureau; Genentech: Research Funding; Janssen: Consultancy, Other: Travel Expenses, Research Funding, Speakers Bureau; Ohio State University: Patents & Royalties: OSU-2S; Genentech: Research Funding; Novartis: Other: Travel Expenses, Speakers Bureau; BeiGene: Research Funding; TG Therapeutics: Other: Travel Expenses, Research Funding, Speakers Bureau; Novartis: Other: Travel Expenses, Speakers Bureau; Pharmacyclics LLC, an AbbVie Company: Other: Travel Expenses, Research Funding, Speakers Bureau; Acerta: Research Funding; Ohio State University: Patents & Royalties: OSU-2S; Ohio State University: Patents & Royalties: OSU-2S; Gilead: Other: Travel Expenses, Research Funding, Speakers Bureau; Genentech: Research Funding; Acerta: Research Funding; BeiGene: Research Funding; Gilead: Other: Travel Expenses, Research Funding, Speakers Bureau; Janssen: Consultancy, Other: Travel Expenses, Research Funding, Speakers Bureau; Pharmacyclics LLC, an AbbVie Company: Other: Travel Expenses, Research Funding, Speakers Bureau.
Teses / dissertações sobre o assunto "(Alliance, Ohio)"
1
Kenreich, Todd W. "Teacher consultants in the Ohio geographic alliance : their beliefs, classroom practices, and professional development activities /". The Ohio State University, 2000. http://rave.ohiolink.edu/etdc/view?acc_num=osu1488202171195451.
Texto completo da fonte
2
Lukes, Laura Ann. "The Alliance, Ohio, earthquake of August 2000 : an examination of felt reports and surficial deposit correlation /". Columbus, Ohio : Ohio State University, 2002. http://hdl.handle.net/1811/6106.
Texto completo da fonte
3
Wilder, Shannon Q. "Creating an Educational Outreach Program in Southwest Ohio: The First Year of Watershed Alliance Volunteer Eco-team (WAVE)". Miami University / OhioLINK, 2010. http://rave.ohiolink.edu/etdc/view?acc_num=miami1272841707.
Texto completo da fonte
4
Skowronski, Mark A. "DIRECT LAND PROTECTION BY CHAGRIN RIVER LAND CONSERVANCY: A NONPROFIT LAND TRUST IN NORTHEAST OHIO". Miami University / OhioLINK, 2003. http://rave.ohiolink.edu/etdc/view?acc_num=miami1049758737.
Texto completo da fonte
5
Wilks, Chrisanne. "Factors Associated with Client Satisfaction at Community-based Mental Health Agencies in Ohio". The Ohio State University, 2015. http://rave.ohiolink.edu/etdc/view?acc_num=osu1448966548.
Texto completo da fonte
6
Sauder, Muhlfeld Sharon M. "Ambiguous alliances: Native American efforts to preserve independence in the Ohio Valley, 1768-1795". W&M ScholarWorks, 2007. https://scholarworks.wm.edu/etd/1539623331.
Texto completo da fonteResumo:
"Ambiguous Alliances" examines the revolutionary era in the Ohio Valley from a Native American perspective. Rather than simply considering them as British pawns or troublesome mischief-makers, this account describes how Wyandots, Shawnees, Ottawas, Delawares, Miamis, and their native neighbors made decisions about war and peace, established alliances with Europeans, Americans, and distant Indian nations, and charted specific strategies for their political and cultural survival. They also suffered devastating personal and property loss and encountered significant disruption to their societal routines. Yet much about their daily lives remained unchanged, and their communities continued to foster a strong Indian identity.;This dissertation explores native objectives for the period 1768--1795, specifically looking at what the various nations were hoping to accomplish in their relationships with the British and the Americans. While preserving land and sovereignty were the Indians' clearest aims, this study also emphasizes that the underlying goal of protecting their rights and property was to retain their cultural distinctiveness. Furthermore, these twin objectives were inextricably linked. The Indians' ability to remain viable diplomatic partners with the Europeans depended on the maintenance of their landed independence.;Along with analyzing native objectives, this dissertation discusses Indian strategies to attain these goals and looks at how the Revolution assisted or hampered their execution. Some tribes actively recruited British or American allies; some attempted to remain neutral; others endeavored to form a united Indian front; and still others alternately extended their allegiance to both parties in an effort to secure both autonomy and protection.;Despite its heavy emphasis on native alliances and military maneuvers, this work also examines the Revolution's challenges to the rhythms of daily life. In addition to physical destruction, wartime agendas altered native.economic patterns and sometimes even invaded cultural practices, threatening to constrict gender roles for women or to prevent nations from adopting captives to replace their deceased relatives. Although the era's disruptions brought emotional distress, physical displacement, and political ambiguity, the tribes persisted in sustaining both their daily existence and their national identities.
7
Bishop, Madison. "Taking Up Space: Community Formation Among Non-Urban LGBTQ Youth". Oberlin College Honors Theses / OhioLINK, 2015. http://rave.ohiolink.edu/etdc/view?acc_num=oberlin1431882184.
Texto completo da fonte
8
Awoshakin, Olatokunbo A. "Higher Education, Citizens Engagement and Economic Development Work at the Grassroots: A Case Study of Dayton, Southwest Ohio". Antioch University / OhioLINK, 2013. http://rave.ohiolink.edu/etdc/view?acc_num=antioch1366824546.
Texto completo da fonteLivros sobre o assunto "(Alliance, Ohio)"
1
National Institute for Occupational Safety and Health, ed. SANCAP Abrasives, Inc.: Alliance, Ohio. [Atlanta, Ga.?]: U.S. Dept. of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, 1994.
Encontre o texto completo da fonte
2
Alliance Genealogical Society (Alliance, Ohio), ed. Post office records of Alliance, Ohio. [Alliance, Ohio]: Alliance Genealogical Society, 2005.
Encontre o texto completo da fonte
3
Alliance Genealogical Society (Alliance, Ohio), ed. Alliance City Cemetery burial records, ca. 1870-1997: Alliance, Ohio, Stark County. [Alliance, Ohio]: Alliance Genealogical Society, 1999.
Encontre o texto completo da fonte
4
Griffiths, George R. A Ford, Gillis alliance from Delaware to Ohio. Chandler, AZ: G.R. Griffiths, 1994.
Encontre o texto completo da fonte
5
Ohio) Alliance Genealogical Society (Alliance. Alliance city cemetery inscriptions, every name index for cemetery inscriptions, Stark County, Ohio, volume 1, pp. 1-150. Alliance, Ohio: Alliance Genealogical Society, 1999.
Encontre o texto completo da fonte
6
Ohio) Alliance Genealogical Society (Alliance. Cassaday-Turkle-Christian funeral records, 1884-1928: Alliance, Ohio, Stark County. Alliance, Ohio: Alliance Genealogical Society, 1999.
Encontre o texto completo da fonte
7
Kelble, Judy Chapin. Gospel Tabernacle of the Christian & Missionary Alliance: Now known as Norwalk Alliance Church, Norwalk, Ohio : her first 75 years, 1928-2003 : her beginnings, her continuance, in the Lord--. Ohio?: s.n., 2003.
Encontre o texto completo da fonte
8
Utt, Robin Kaye. Science Hill Community Church: A 175 year history celebration of a small community church. Alliance, Ohio (P.O. Box 3630, Alliance 44601)]: Alliance Genealogical Society, 2008.
Encontre o texto completo da fonte
9
Musson, Robert A. Brewing beer in the Mahoning valley: A pictorial history of the brewing industry in Alliance, Warren, Niles, and Youngstown, Ohio, and New Castle, Pennsylvania. Medina, OH: Zepp Publications, 2011.
Encontre o texto completo da fonte
10
Lewis, Faba. John C. Freemont Post 729 GAR applications. Alliance, OH: The Alliance Genealogical Society, 2006.
Encontre o texto completo da fonteCapítulos de livros sobre o assunto "(Alliance, Ohio)"
1
"Alliance". In Little Ohio, 1–3. Indiana University Press, 2023. http://dx.doi.org/10.2307/j.ctv34wmx36.4.
Texto completo da fonte
2
Kheng, Liz. "Ohio School Health Services Association (OSHSA) Case Study". In Trends, Challenges, and Practices in Contemporary Strategic Management, 168–93. IGI Global, 2024. http://dx.doi.org/10.4018/979-8-3693-1155-4.ch009.
Texto completo da fonteResumo:
This case study provides a comprehensive overview of the Ohio School Health Services Association (OSHSA) and its collaborative management efforts within the education and healthcare services domain for school-aged children in Ohio. While utilizing the lens of strategic management, the case study underscores Medicaid, a government-sponsored healthcare program, as a critical initiative aligning state and federal resources to provide essential healthcare services for students. OSHSA represents a strategic partnership, integrating the collaborative efforts of educational institutions, Medicaid billing agents, healthcare practitioners, and governmental bodies to ensure optimal healthcare accessibility for students. Furthermore, this case study will illuminate the organization's mission, objectives, and strategic partnerships. The case study will highlight how strategic management principles guide the organization's operations, fostering alliances with government agencies and lobbyists to advocate for improved healthcare provisions for Ohio students.
3
Robinson, D. H. "‘Giving Peace to Europe’". In The Idea of Europe and the Origins of the American Revolution, 131–73. Oxford University Press, 2020. http://dx.doi.org/10.1093/oso/9780198862925.003.0005.
Texto completo da fonteResumo:
This chapter looks at colonial attitudes to British foreign policy during the War of the Austrian Succession (1740–8), the brief peace of 1748–57, and the Seven Years War (1757–63). It touches on themes including the balance of power, the Hanoverian connection, the Austrian, Prussian, and Dutch alliances, the Diplomatic Revolution of 1756, and the Treaties of Aix-la-Chapelle (1748) and Paris (1763). It follows how colonists understood struggles with France and Spain in the Americas within these larger conflicts, from the capture of Louisbourg by the Massachusetts militia in 1745 to events in the Ohio Valley in the mid-1750s, and came to view the colonies as part of the European geopolitics system. And it explores how colonial and metropolitan sentiments about European warfare began to diverge during these conflicts.
4
Seeley, Samantha. "The Tools of “Civilization”". In Race, Removal, and the Right to Remain, 137–70. University of North Carolina Press, 2021. http://dx.doi.org/10.5149/northcarolina/9781469664811.003.0005.
Texto completo da fonteResumo:
After the Revolution, Native confederationists traveled across eastern North America to form military alliances to rival the United States. US officials indicted Indigenous people as peculiarly mobile, and they believed that movement proved Native peoples to be unsteady in their political attachments or without rights to land. U.S agents held only paper claims to power in Indian country, but they hoped that the control of movement would make those paper claims real. Early national policy—“civilization” plans, trading houses, the imposition of federal law—turned on the conceit of “attaching” Native people to the United States. All of these programs were designed to further removal by thwarting movement as a strategy of resistance. The early nineteenth century was a period of profound social change for Native Americans north of the Ohio River. That change was rooted as much in a contest over movement as it was in a contest over religion, political economy, and culture. In the early national period, the “problem” of mobility conversely emerged as a battleground in Native struggles for the right to remain east of the Mississippi River.
Trabalhos de conferências sobre o assunto "(Alliance, Ohio)"
1
Abrams, Richard F., Kevin Toupin, John T. Costa e Ned Popovic. "2,400 Tons Per Day Refuse Derived Fuel Facility With Advanced Boiler and Air Pollution Control Systems". In 18th Annual North American Waste-to-Energy Conference. ASMEDC, 2010. http://dx.doi.org/10.1115/nawtec18-3549.
Texto completo da fonteResumo:
A greenfield Refuse Derived Fuel (RDF) facility in Alliance Ohio will process 2,400 Tons Per Day (TPD) of Municipal Solid Waste (MSW) and Construction & Demolition Debris (C&D). The Ohio EPA has issued the final air permit for the facility. There will be two equipment trains to handle the material each consisting of Riley Power’s Advanced Stoker™ boiler, Turbosorp® dry scrubber, and Regenerative Selective Catalytic Reduction (RSCR®) nitrogen oxides (NOx) control system. The key parts of the “chute to stack” equipment represent a significant advancement in technology when compared to past facilities, as demonstrated by the designation by the State of Ohio as an “Advanced Energy Project”. The Riley Advanced Stoker™ boiler has unique design features to ensure high efficiency, corrosion resistance, and fuel flexibility while at relatively low cost. The use of the Turbosorp will result in lower emissions of lead, other volatile heavy metals, and mercury than for a typical spray dryer/baghouse (SDA) system. Acid gas removal is also superior to an SDA system while utilizing less lime reagent and power. The RSCR follows the Turbosorp as a “low dust” SCR but with auxiliary energy consumption about 85% lower than a typical low dust, tail end SCR. The RSCR will reduce NOx and Carbon Monoxide (CO) emissions to low values when compared to other facilities producing energy from waste. This paper will describe the design basis for the system including fuels to be processed, steam flow and conditions, and emissions. A detailed description of the technologies will also be presented.
2
Turner, Kevin E., Michael Dunn e Corso Padova. "Airfoil Deflection Characteristics During Rub Events". In ASME Turbo Expo 2010: Power for Land, Sea, and Air. ASMEDC, 2010. http://dx.doi.org/10.1115/gt2010-22166.
Texto completo da fonteResumo:
The turbomachinery industry continually struggles with the adverse effects of contact rubs between airfoils and casings. The key parameter controlling the severity of a given rub event is the contact load produced when the airfoil tips incur into the casing. These highly non-linear and transient forces are difficult to calculate and their effects on the static and rotating components are not well understood. To help provide this insight, experimental and analytical capabilities have been established and exercised through an alliance between GE Aviation and The Ohio State University Gas Turbine Laboratory. One of the early findings of the program is the influence of blade flexibility on the physics of rub events. The focus of this paper is to quantify the influence of airfoil flexibility through a novel modeling approach that is based on the relationship between applied force duration and maximum tip deflection. Results from the model are compared to experimental results, providing sound verification.
3
Ghezel-Ayagh, Hossein, Anthony J. Leo, Hans Maru e Mohammad Farooque. "Overview of Direct Carbonate Fuel Cell Technology and Products Development". In ASME 2003 1st International Conference on Fuel Cell Science, Engineering and Technology. ASMEDC, 2003. http://dx.doi.org/10.1115/fuelcell2003-1697.
Texto completo da fonteResumo:
Significant progress has been made in development of power generation products based on carbonate fuel cells. Carbonate fuel cell systems provide high efficiency and ultra-clean power generation from a variety of gaseous, liquid, and solid carbonaceous fuels. The high operating temperature of 650 °C in carbonate fuel cell allows significant system simplification by integrating the internal reforming feature into the fuel cell stack as well as use of the byproduct heat in an efficient bottoming cycle. Direct FuelCell® (DFC®) is a unique version of the carbonate fuel cell, which generates electricity directly from a hydrocarbon fuel by reforming the fuel inside the fuel cell and producing hydrogen. The direct reforming concept eliminates the need for an external reformer resulting in power plants with reduced capital cost. This feature also allows the DFC power plants to utilize the existing fuel distribution infrastructure. The first generation of products offered by FuelCell Energy (FCE) range from 250kW to 2MW and is suitable to operate on natural gas, digester gas and other fuels. Presently, a fleet of natural gas fueled units is operating in the US and Europe at customers’ sites. Additionally, there are subsequent power plants planned to operate on a variety of fuels, including coal-bed methane, digester gas, and coal-derived gas. A 2 MW fuel cell power plant (DFC3000) will soon be operating with coal gas in Wabash River, Indiana’s coal gasification plant. The field tests of a 1 MW unit (DFC1500) at King County (Seattle, WA) waste treatment will be demonstrating the unique features of the DFC technology with digester gas as a fuel. There are plans to operate a 250 kW (DFC300) unit on coal-bed methane fields in Cadiz, Ohio. FCE is also developing a 500 kW unit for the US NAVY, operating on marine distillate fuels. FCE is also developing fuel cell/turbine ultra-high efficiency hybrid power plants with efficiencies approaching 75%. In the Direct FuelCell/Turbine® (DFC/T®) power cycle, the fuel cell is integrated with an indirectly heated gas turbine. FCE has recently completed the operation of a ‘proof-of-concept’ system that combined a sub-megawatt DFC with a 30-kilowatt microturbine. The proof-of-concept tests demonstrated that the DFC/T hybrid concept, indeed, has the potential for achieving higher efficiencies than the single cycle fuel cell. The demonstration of two, packaged sub-megawatt DFC/T units, one in Danbury and one at a customer site in Montana, is planned. In addition to pioneering the Direct FuelCell technology, FCE has established a strong manufacturing base. Currently the manufacturing facility at Torrington, CT, has the equipment in place to produce 50 MW per year of fuel cells. FCE has also established commercial distribution alliances with electric power equipment sales and service companies, energy service and solution providers, and specialty application developers for marketing DFC products. The operation of FCE’s power plants at customer sites, continuing efforts in technology improvement, and the favorable reception of the customers for DFC-based units, combined with a network of partners for sales and services, are the key factors for market penetration of DFC products.
Relatórios de organizações sobre o assunto "(Alliance, Ohio)"
1
Adams, Sunny, e Madison Story. Architectural survey of eight Ohio Army National Guard armories, 1971–1977. Engineer Research and Development Center (U.S.), maio de 2023. http://dx.doi.org/10.21079/11681/47092.
Texto completo da fonteResumo:
This document is an architectural survey of eight armories, seven field maintenance shops (FMS; three detached and four attached to the armory), and ten metal storage buildings utilized by the Ohio Army National Guard (OHARNG), located across the state of Ohio. The armories and OMS were constructed or received extensive renovation and additions between 1971 and 1977, while the majority of the metal storage buildings were constructed in the 1980s. This survey satisfies Section 110 of the National Historic Preservation Act of 1966 (NHPA) as amended and was used to recommend the eligibility of these buildings and structures for inclusion on the National Register of Historic Places (NRHP). It is the recommendation of this report that two armories; Alliance Armory (1976) and Xenia Armory (1975) and one associated support building; Xenia motor storage building (1975) are significant under National Register of Historic Places criteria and retain enough integrity to be individually eligible for the NRHP. Volume II of this report is published separately and contains the ERDC-CERL architectural survey forms.
2
Health hazard evaluation report: HETA-84-186-1777, Sancap Abrasives, Inc., Alliance, Ohio. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, National Institute for Occupational Safety and Health, fevereiro de 1987. http://dx.doi.org/10.26616/nioshheta841861777.
Texto completo da fonte
3
Health hazard evaluation report: HETA-92-0001-2444, SANCAP Abrasives, Inc., Alliance, Ohio. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, agosto de 1994. http://dx.doi.org/10.26616/nioshheta9200012444.
Texto completo da fonte